Press releases

02 November 2022 | 02:05 PM

Dr Michael Lichtenberg today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22

HORSHAM, UK – 01 Nov 2022 – Veryan Medical Ltd announces that Dr Michael Lichtenberg (Klinikum Hochsauerland, Arnsberg, Germany) today […]

Read more

07 October 2022 | 10:21 AM

BioMimics 3D® Vascular Stent System granted Good Design Award 2022

TOKYO, JAPAN – 07 OCTOBER 2022 – Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”, subsidiary of Otsuka Holdings Co., […]

Read more

01 May 2022 | 01:03 PM

BioMimics 3D®, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration

HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and […]

Read more

06 April 2021 | 03:14 PM

Veryan Medical announces multimillion-euro investment in Galway operation

Galway, 06 April 2021 Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further […]

Read more

16 December 2020 | 03:28 PM

First patient enrolment in MIMICS 3D USA

Veryan Medical (Horsham, UK) is delighted to announce that the first patient was enrolled today in the MIMICS-3D USA study […]

Read more

Featured story

01 September 2022

Board Announcement –

Appointment of new CEO

HORSHAM, UK – 01 SEPTEMBER 2022 – The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals.

More stories

BioMimics 3D US launch

Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up.

36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live

Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live.

Events

View the latest international events Veryan will be participating in.

More from Veryan

Our innovative approach

Our approach to design intelligence focuses on using our intuition and experiential perceptions to understand the key challenges and to achieve our goals.

Who we are

To accomplish great things we need to act but also to dream, not only to plan but also to believe.

Clinical Evidence

See what upcoming events Veryan is participating in.